PartnerRe Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

PartnerRe Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,515	Closed	-$211K	–	443
2016 Q1	$211K	Hold	1,515	–	–	0.11%	145
2015 Q4	$289K	Sell	1,515 -2,578	-63%	-$450K	0.15%	106
2015 Q3	$640K	Buy	4,093 +49	+1%	+$8.94K	0.11%	134
2015 Q2	$731K	Sell	4,044 -239	-6%	-$41.2K	0.14%	129
2015 Q1	$742K	Buy	4,283 +60	+1%	+$10.9K	0.12%	142
2014 Q4	$781K	Buy	4,223 +602	+17%	+$112K	0.13%	138
2014 Q3	$600K	Sell	3,621 -585	-14%	-$96.1K	0.12%	149
2014 Q2	$657K	Sell	4,206 -575	-12%	-$90.8K	0.12%	162
2014 Q1	$727K	Buy	4,781 +61	+1%	+$9.7K	0.12%	158
2013 Q4	$627K	Sell	4,720 -264	-5%	-$31.7K	0.11%	171
2013 Q3	$579K	Sell	4,984 -647	-11%	-$71K	0.1%	181
2013 Q2	$519K	Buy	+5,631	New	+$543K	0.08%	211

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PartnerRe Asset Management's ALXN Position: Q2 2016 in Review

PartnerRe Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 1,515 shares — an estimated $211K sold.

PartnerRe Asset Management first reported a position in ALXN in Q2 2013 and held it in 12 quarters. The position peaked at $781K in Q4 2014. 534 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

PartnerRe Asset Management reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
PartnerRe Asset Management sold 1,515 Alexion Pharmaceuticals shares in Q2 2016, an estimated $211K.
PartnerRe Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
PartnerRe Asset Management's Alexion Pharmaceuticals position peaked at $781K in Q4 2014.
534 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on PartnerRe Asset Management's 13F filing for Q2 2016, filed 14 Jul 2016.